Healthcare
Molecular Partners AG(MLLCF)
Live Price
Offline$4.85
+0.00% today
1Y Change
-14.69%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $120.00M
- Revenue Growth
- -100.0%
- EPS Growth
- -1.2%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Molecular Partners AG (MLLCF) is a Healthcare stock with a market cap of $120.00M and listed on OTC. The stock last traded around $4.85 and down 14.7% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of -1.2%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS -1.2%, free cash flow +16.2% with operating margin 0.0% and ROIC -62.9%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MLLCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at -1.2%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +0.0% | +0.0% | +90.2% |
2026 Mar 12, 2026 | -9.7% | +0.0% | +0.0% | +3.6% |
2025 Oct 30, 2025 | +14.4% | +0.0% | +0.0% | +0.0% |
Benchmark Edge
MLLCF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MLLCF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MLLCF Max Drawdown
-46.68%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MLLCF and SPY.
Company Overview
Molecular Partners AG
Other OTC
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
- Leadership
- Patrick Amstutz
- IPO Date
- Jun 14, 2018
- Employees
- 158
- Street Address
- Wagistrasse 14
- Mailing
- Schlieren, 8952
- Region
- Schlieren, CH
- Reporting Currency
- USD
- Investor Line
- 41 44 755 77 00
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 1.5
Growth
- Revenue
- -100.0%
- EPS
- -1.2%
- Free Cash Flow
- +16.2%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -60.1%
- ROIC
- -62.9%
Balance Sheet
- Debt/Equity
- 0.05
- Current Ratio
- 8.79
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.